Lin Cheng-Kai, Chen Po-Yuan, Wu Yu-Ying, Wu Cheng-Chun, Chen Han-Jung, Liang Cheng-Loong, Lee Yi-Che, Lin Chi-Wei, Hung Chao-Ming, Wang Hao-Kuang
School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
Department of Neurosurgery, E-Da Hospital, Kaohsiung, Taiwan.
Risk Manag Healthc Policy. 2021 Jan 14;14:177-183. doi: 10.2147/RMHP.S290964. eCollection 2021.
Statin treatment improves clinical outcomes in patients with ischemic strokes, although there is no evidence regarding the safety of statin therapy in patients with intracerebral hemorrhage (ICH). This study aimed at evaluating the effects of continuing statin treatment after ICH.
Data were obtained from the National Health Insurance Research Database in Taiwan. We retrospectively compared the data of patients with and without statin exposure after ICH. The outcomes of interest were recurrence of hemorrhagic stroke and mortality during a follow-up period of 10 years.
During the 10-year follow-up period, the mortality rate was 32.73% in the statin group and 42.77% in the non-statin group. Statin therapy in patients with acute ICH with dyslipidemia can decrease mortality.
Statin therapy reduced the risk of 10-year mortality in patients who experienced acute hemorrhagic stroke.
他汀类药物治疗可改善缺血性卒中患者的临床预后，尽管尚无关于他汀类药物治疗对脑出血（ICH）患者安全性的证据。本研究旨在评估脑出血后继续使用他汀类药物治疗的效果。
数据来自台湾国民健康保险研究数据库。我们回顾性比较了脑出血后使用和未使用他汀类药物的患者数据。感兴趣的结局是10年随访期内出血性卒中复发和死亡率。
在10年随访期内，他汀类药物组的死亡率为32.73%，非他汀类药物组为42.77%。急性脑出血合并血脂异常患者使用他汀类药物治疗可降低死亡率。
他汀类药物治疗降低了急性出血性卒中患者10年死亡风险。
